135 related articles for article (PubMed ID: 11465809)
21. Cisplatin pharmacokinetics and pharmacodynamics in patients with squamous-cell carcinoma of the head/neck or esophagus.
Johnsson A; Höglund P; Grubb A; Cavallin-Ståhl E
Cancer Chemother Pharmacol; 1996; 39(1-2):25-33. PubMed ID: 8995496
[TBL] [Abstract][Full Text] [Related]
22. Microalbuminuria during cisplatin therapy: relation with pharmacokinetics and implications for nephroprotection.
Kern W; Braess J; Kaufmann CC; Wilde S; Schleyer E; Hiddemann W
Anticancer Res; 2000; 20(5C):3679-88. PubMed ID: 11268439
[TBL] [Abstract][Full Text] [Related]
23. Mesna excretion and ifosfamide nephrotoxicity in children.
Goren MP; Pratt CB; Meyer WH; Wright RK; Dodge RK; Viar MJ
Cancer Res; 1989 Dec; 49(24 Pt 1):7153-7. PubMed ID: 2510931
[TBL] [Abstract][Full Text] [Related]
24. Reduced ability to clear ultrafilterable platinum with repeated courses of cisplatin.
Reece PA; Stafford I; Russell J; Gill PG
J Clin Oncol; 1986 Sep; 4(9):1392-8. PubMed ID: 3746376
[TBL] [Abstract][Full Text] [Related]
25. Population pharmacokinetic analysis of cisplatin and its metabolites in cancer patients: possible misinterpretation of covariates for pharmacokinetic parameters calculated from the concentrations of unchanged cisplatin, ultrafiltered platinum and total platinum.
Hanada K; Nishijima K; Ogata H; Atagi S; Kawahara M
Jpn J Clin Oncol; 2001 May; 31(5):179-84. PubMed ID: 11450990
[TBL] [Abstract][Full Text] [Related]
26. Quantitative relationship between pharmacokinetics of unchanged cisplatin and nephrotoxicity in rats: importance of area under the concentration-time curve (AUC) as the major toxicodynamic determinant in vivo.
Nagai N; Ogata H
Cancer Chemother Pharmacol; 1997; 40(1):11-8. PubMed ID: 9137523
[TBL] [Abstract][Full Text] [Related]
27. The role of complement activation, detected by urinary C5b-9 and urinary factor H, in the excretion of urinary albumin in cisplatin nephropathy.
Fuke Y; Fujita T; Satomura A; Endo M; Matsumoto K
Clin Nephrol; 2009 Feb; 71(2):110-7. PubMed ID: 19203502
[TBL] [Abstract][Full Text] [Related]
28. Cisplatin nephrotoxicity: a multivariate analysis of potential predisposing factors.
Lagrange JL; Médecin B; Etienne MC; Pivot X; Cassuto-Viguier E; Renée N; Thyss A; Ferrero JM; Otto J; François E; Milano G
Pharmacotherapy; 1997; 17(6):1246-53. PubMed ID: 9399607
[TBL] [Abstract][Full Text] [Related]
29. A pharmacokinetic study of high-dose continuous infusion cisplatin in children with solid tumors.
Dominici C; Petrucci F; Caroli S; Alimonti A; Clerico A; Castello MA
J Clin Oncol; 1989 Jan; 7(1):100-7. PubMed ID: 2909663
[TBL] [Abstract][Full Text] [Related]
30. A phase I trial of continuous infusion cisplatin.
Posner MR; Ferrari L; Belliveau JF; Cummings FJ; Wiemann MC; O'Rourke A; Weitberg AB; Calabresi P
Cancer; 1987 Jan; 59(1):15-8. PubMed ID: 3791142
[TBL] [Abstract][Full Text] [Related]
31. Comparison of methods of evaluating nephrotoxicity of cis-platinum.
Jones BR; Bhalla RB; Mladek J; Kaleya RN; Gralla RJ; Alcock NW; Schwartz MK; Young CW; Reidenberg MM
Clin Pharmacol Ther; 1980 Apr; 27(4):557-62. PubMed ID: 6987030
[TBL] [Abstract][Full Text] [Related]
32. Correlation between free platinum AUC and total platinum measurement 24 h after i.v. bolus injection of cisplatin in humans.
Fournier C; Vennin P; Hecquet B
Cancer Chemother Pharmacol; 1988; 21(1):75-7. PubMed ID: 3342469
[TBL] [Abstract][Full Text] [Related]
33. Effect of buthionine sulphoximine, glutathione and methimazole on the renal disposition of cisplatin and on cisplatin-induced nephrotoxicity in rats: pharmacokinetic-toxicodynamic analysis.
Hanada K; Mukasa Y; Nomizo Y; Ogata H
J Pharm Pharmacol; 2000 Dec; 52(12):1483-90. PubMed ID: 11197076
[TBL] [Abstract][Full Text] [Related]
34. Continuous infusion of high-dose cisplatin in children: pharmacokinetics of free and total platinum.
Bues-Charbit M; Gentet JC; Bernard JL; Breant V; Cano JP; Raybaud C
Eur J Cancer Clin Oncol; 1987 Nov; 23(11):1649-52. PubMed ID: 3428333
[TBL] [Abstract][Full Text] [Related]
35. Nephrotoxicity of cis-platinum (II) dichlorodiammine.
Stark JJ; Howel SB
Clin Pharmacol Ther; 1978 Apr; 23(4):461-6. PubMed ID: 415836
[TBL] [Abstract][Full Text] [Related]
36. Long-term renal effect of cisplatin in man.
Brillet G; Deray G; Jacquiaud C; Mignot L; Bunker D; Meillet D; Raymond F; Jacobs C
Am J Nephrol; 1994; 14(2):81-4. PubMed ID: 8080010
[TBL] [Abstract][Full Text] [Related]
37. Pharmacokinetic-Pharmacodynamic Analysis of Cisplatin with Hydration and Mannitol Diuresis: The Contribution of Urine Cisplatin Concentration to Nephrotoxicity.
Fukushima K; Okada A; Oe H; Hirasaki M; Hamori M; Nishimura A; Shibata N; Sugioka N
Eur J Drug Metab Pharmacokinet; 2018 Apr; 43(2):193-203. PubMed ID: 28913815
[TBL] [Abstract][Full Text] [Related]
38. Epidemiologic Characteristics of Acute Kidney Injury During Cisplatin Infusions in Children Treated for Cancer.
McMahon KR; Rassekh SR; Schultz KR; Blydt-Hansen T; Cuvelier GDE; Mammen C; Pinsk M; Carleton BC; Tsuyuki RT; Ross CJD; Palijan A; Huynh L; Yordanova M; Crépeau-Hubert F; Wang S; Boyko D; Zappitelli M;
JAMA Netw Open; 2020 May; 3(5):e203639. PubMed ID: 32383745
[TBL] [Abstract][Full Text] [Related]
39. Urinary excretion of carnitine as a marker of proximal tubular damage associated with platin-based antineoplastic drugs.
Haschke M; Vitins T; Lüde S; Todesco L; Novakova K; Herrmann R; Krähenbühl S
Nephrol Dial Transplant; 2010 Feb; 25(2):426-33. PubMed ID: 19736245
[TBL] [Abstract][Full Text] [Related]
40. [A prospective study on nephrotoxicity induced by continuous infusion of high-dose ifosfamide (15/m2)].
Ferrari S; Zolezzi C; Bacci G; Pieretti F; Iantorno D; Figus E; Pizzoferrato A
Minerva Pediatr; 1997; 49(1-2):29-37. PubMed ID: 9132558
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
